MAZE THERAPEUTICS INC
MAZE
Health Care
1
exclusion reason
1 theme
This page is part of our public exclusion list — a transparency tool that shows which companies we screen out and why. It is not investment advice, and it is not an accusation. But it is subject to change as our understanding of the facts evolves.
Maze Therapeutics is a preclinical-stage biotechnology company whose drug development pipeline requires animal testing as a standard regulatory step. The company’s SEC filings explicitly state that its potential therapeutic candidates “may be shown to have harmful side effects in animal” studies, confirming that animal models are integral to its research and development process. As a company whose entire business model is predicated on advancing drug candidates through preclinical and clinical trials, the commercial exploitation of animals for testing is a foundational and unavoidable component of its operations.
Research Sources
1 organization
Related Exclusions
Wondering what we do invest in?
The Naughty List
A digest of changes to our exclusion list — new additions, removals, and the evidence behind them. We review the list continuously as new evidence surfaces.
Companies appear on our exclusion list based on our investment judgment — not because they've done anything illegal. This is a difference of values and opinion, not an accusation of wrongdoing. Exclusion does not constitute a recommendation against investing in any company, and absence from the list does not constitute a recommendation to invest.
This information is provided for educational and transparency purposes only and should not be relied upon as investment advice. Data is drawn from independent watchdogs, NGOs, government registries, and Ethical Capital's ongoing research — see Research Sources for the full list.
Ethical Capital LLC is a state-registered investment adviser in Utah (CRD #316032). Registration does not imply a certain level of skill or training.